



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 08/993,696      | 12/18/1997  | DAVID J. SCHANZLIN   | 251692002821        | 5525             |

7590 10/20/2003

Antoinette F. Konski  
McCutchen Doyle Brown & Enersen LLP  
Three Embarcadero Center, Suite 1800  
San Francisco, CA 94111-4067

EXAMINER

WILLSE, DAVID H

ART UNIT PAPER NUMBER

3738

DATE MAILED: 10/20/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

08/993,696

Applicant(s)

SCHANZLIN ET AL.

Examiner

Dave Willse

Art Unit

3738

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 25 September 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 68-103 is/are pending in the application.
- 4a) Of the above claim(s) 68-85 and 94-103 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 86-93 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_ 6) ☐ Other: \_\_\_\_\_

Art Unit: 3738

The Amendment submitted on May 9, 2003, fails to unambiguously identify the locations at which paragraphs of the specification are to be replaced, and the freehand changes are, in some cases, difficult to read. An Amendment in compliance with the revised format under 37 CFR 1.121 must be provided in response to the instant Office action.

The disclosure is objected to because of the following informalities: On page 19, line 23, "my" should be replaced by --may--. On page 25, line 16, "are" should be deleted. On page 36, line 16, "Preferably" is misspelled. *Other errors were noted.* Appropriate correction is required.

The abstract of the disclosure is objected to because it should be "limited to a single paragraph within the range of 50 to 150 words"; correction is required (MPEP § 608.01(b)).

Claims 68-85 and 94-103 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected group or species, there being no allowable generic or linking claim.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various

Art Unit: 3738

claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 86-93 are rejected under 35 U.S.C. 103(a) as being unpatentable over Herrick, US 4,781,187, which employs donor corneal tissue (inherently comprising natural polymers such as collagen and mucopolysaccharide) as the implant material (column 3, lines 41-49). Substituting a synthetic polymer material would have been obvious in order to provide greater control over material properties, to reduce the risk of disease transmission, to ensure availability of materials, and so on, especially in the absence of any advantage or criticality in the instant disclosure of synthetic polymers over natural polymers (*In re Kuhle*, 188 USPQ 9; *Ex parte Clapp*, 227 USPQ 972, 973). In fact, the Applicant's specification states that synthetic or natural polymers may be used (page 1, lines 18-19; page 17, lines 15-17) and even includes collagen as a possible material (original claim 63). And synthetic polymers were well known in the art, as evidenced by the Applicant's statements at page 2, line 24 et seq. of the specification and by prior art references of record. Regarding claims 88 and 89, a radius of curvature within the prescribed ranges would have been immediately obvious from the intended use of the device, as best illustrated by Figures 3, 4, 7, and 9. Regarding claims 91-93, although Herrick specifies typical dimensions "on the order of a length of 3.5 to 4.0 millimeters" (column 3, lines 52-56), lengths as low as 2.0 millimeters would have been obvious in order to accommodate experimentation or practice on rabbits and other small animals or to minimize the length of the corneal incision.

Art Unit: 3738

Claims 86-93 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gonchar et al., "Interlayer Refraction Tunnel Keratoplasty in Correcting Myopia and Astigmatism". The implants being of a synthetic polymer would have been an obvious material variant for reasons provided above with respect to the Herrick patent. Regarding claims 88 and 89, values within the specified ranges would have been immediately obvious from the purpose of the implants (Figure 3). Regarding claims 91-92: page 4, line 16, of the English translation. Regarding claim 93, an implant having a length of 2.0 mm or less would have been obvious in order to accommodate a variety of eye sizes (e.g., page 2, lines 3-4, of said translation) and refractive disorders.

Claims 86, 87, and 90 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Civerchia, US 5,213,720. Regarding the last two lines of claim 86, MPEP 2106, section II. C., explains that language which suggests or makes optional but "does not limit a claim to a particular structure does not limit the scope of a claim or claim limitation"; "examples of language that may raise a question as to the limiting effect of the language in a claim" are "adapted to" and "adapted for" clauses. The embodiments shown in Figures 14 and 17 can be inserted into the cornea (Figure 4; column 6, lines 20-21; column 18, lines 9-12) and thus possess a radius of curvature along a centroidal axis of at least 5.0 mm; because of their elongate form, these embodiments clearly extend in a meridional direction.


Claims 88, 89, and 91-93 are rejected under 35 U.S.C. 103(a) as being unpatentable over Civerchia, US 5,213,720. Regarding claims 88 and 89, the particular radius of curvature would have been immediately obvious from the anatomy depicted in Figure 4. Regarding claims 91-93,

Art Unit: 3738

the length of the tabs 132 being less than or equal to 2.0 mm would have been obvious from the drawing (Figure 17) and would have been obvious in order to lessen the trauma to the cornea.

The Applicant's remarks have been reviewed and are adequately addressed in the grounds of rejection presented above.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dave Willse whose telephone number is (703) 308-2903. The examiner can normally be reached Monday through Thursday and often on Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott, can be reached on (703) 308-2111. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0858.

  
Dave Willse  
Primary Examiner  
Art Unit 3738